Clinical Trial

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-02
notable Primary completion pushed: 2026-03-26 -> 2026-09-26 2026-05-02
minor Completion pushed: 2026-07-28 -> 2026-09-28 2026-05-02
Trial Details
NCT Number NCT07350577
Lead Sponsor AltruBio Inc.
Conditions Ulcerative Colitis (UC)
Enrollment 24 participants
Start Date 2025-11-17
Primary Completion 2026-09-26 (estimated)
Study Completion 2026-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-01